BMS didn’t want to choose between clinical expertise and financial know-how when selecting a new strategy leader. The Big ...

The Alliance for Regenerative Medicine has voiced deep disappointment about reports that the FDA has put the director of its ...

Arialys Therapeutics' precision medicine has shown preclinical potential to address the underlying cause of anti-NMDA ...

Biotech has always been a little unconventional, but, as the industry’s bear market drags on, efforts to stay afloat are ...

The FDA has stopped new clinical trials that export American citizens’ living cells from the U.S. to “China and other hostile ...

In May, the company announced the failure of the monoclonal antibody birtamimab to improve mortality in a phase 3 trial of ...

Life sciences investment firm Syncona has blamed the “particularly challenging” market conditions for shifting its strategy ...

Multiple developers of connected diabetes hardware have announced plans this week to link their insulin pumps with continuous ...

The miniaturized surgical robot maker Virtual Incision has pinched a new CEO, as it aims to expand its commercial reach ...

Caris Life Sciences bumped up the pricing of its IPO to raise more than $494.1 million in its Nasdaq debut—well over the ...

A new biotech has come roaring to life in Wales with a $140 million series A and a lead candidate ready for phase 2 trials in ...

Immuneering has reported 94% overall survival (OS) at six months in first-line pancreatic cancer, emboldening the biotech to ...